Global Coartem (Artemether/Lumefantrine) Market Size By Type (Artemether, Lumefantrine), By Application (Hospital Pharmacy, Retail Pharmacy), By Region, And Segment Forecasts, 2023 to 2032

The Global Coartem (Artemether/Lumefantrine) Market was valued at USD 590 million in 2023 and is projected to reach USD 885 million by 2031, growing at a CAGR of 5.2% during the forecast period from 2023 to 2031. The increasing global burden of malaria, particularly in tropical and subtropical regions, remains a primary driver for the sustained demand for Coartem. As a leading artemisinin-based combination therapy (ACT), Coartem plays a crucial role in national and international malaria control programs. Enhanced access to public health funding, improved healthcare infrastructure in developing nations, and strategic procurement by organizations like WHO and UNICEF are also contributing to market growth.

Drivers

1. Rising Global Incidence of Malaria:

Despite declining malaria-related mortality in recent years, the disease remains prevalent in many regions, especially Sub-Saharan Africa and parts of Southeast Asia. Coartem continues to be a first-line treatment option due to its proven efficacy.

2. International Health Initiatives and Funding:

Support from the Global Fund, WHO, and various NGOs for malaria elimination campaigns is boosting the supply and distribution of ACTs like Coartem, especially in high-burden countries.

3. Proven Therapeutic Efficacy and Safety:

Coartem’s strong clinical track record for safety, effectiveness, and rapid parasite clearance drives its continued adoption in public and private healthcare systems.

Restraints

1. Drug Resistance Concerns:

Emerging resistance to artemisinin in regions such as the Greater Mekong Subregion poses a significant threat to long-term efficacy and market stability.

2. Dependence on Public Sector Procurement:

A major share of the demand for Coartem comes from public health systems and NGOs. Any fluctuation in donor funding or policy shifts can directly affect market dynamics.

Opportunity

1. Expansion into Emerging and Underdiagnosed Regions:

Opportunities exist to improve malaria diagnosis and treatment in underpenetrated regions, including rural Latin America and parts of Central Africa.

2. Development of Pediatric and Fixed-Dose Variants:

Innovations such as child-friendly formulations and heat-stable dosage forms offer potential to increase access and compliance in vulnerable populations.

3. Integration with Community Health Initiatives:

Expanding community-based distribution models and integrating malaria treatment with maternal and child health programs can broaden Coartem’s reach.

Market by System Type Insights

Coartem is primarily segmented by formulation type, including:

Tablets (Standard and Dispersible): These are the most widely used formulations, accounting for the majority of prescriptions.

Injectable Artemether: Though not a direct Coartem product, its combination with lumefantrine in some regional programs reflects evolving treatment regimens.

In 2023, tablet formulations led the market due to their convenience, proven effectiveness, and WHO prequalification for widespread use.

Market by End-use Insights

By end-use, the market is divided into:

Public Health Institutions

Private Healthcare Providers

Pharmacies/Drug Retailers

The public health institutions segment held over 60% of the market share in 2023. These institutions play a critical role in malaria control programs, especially in endemic regions with government-subsidized access.

Market by Regional Insights

Geographically, Africa remains the largest and most critical market for Coartem, accounting for more than 70% of global usage due to the high malaria burden. Countries like Nigeria, Democratic Republic of the Congo, and Uganda are key demand centers.

Asia-Pacific is projected to be the fastest-growing region, driven by initiatives to eliminate malaria in countries like India, Myanmar, and Papua New Guinea.

Latin America and Middle East & North Africa (MENA) represent smaller but growing markets as surveillance and treatment access improve.

Competitive Scenario

Novartis AG dominates the global Coartem market as the original developer and sole WHO-prequalified supplier for many public health procurement programs. Other players involved in related ACT markets include:

Cipla Ltd.

Ipca Laboratories

Sanofi

Guilin Pharmaceutical Co., Ltd.

Macleods Pharmaceuticals

These companies focus on cost-effective generics, fixed-dose combinations, and localized distribution partnerships.

Scope of Work – Global Coartem (Artemether/Lumefantrine) Market

Key Market Developments

2023: Novartis expanded its access agreement with the Global Fund to increase the availability of Coartem Dispersible for pediatric malaria treatment in Sub-Saharan Africa.

2024: Sanofi announced a partnership to co-develop heat-stable artemether-lumefantrine formulations suitable for storage in tropical climates.

2025: Cipla launched a regionally approved generic Coartem equivalent in select Southeast Asian countries.

FAQs

What is the current market size of the Global Coartem (Artemether/Lumefantrine) Market?

The market was valued at USD 590 million in 2023.

What is the major growth driver of the Global Coartem (Artemether/Lumefantrine) Market?

The primary driver is the rising global incidence of malaria, especially in tropical regions.

Which is the largest region during the forecast period in the Global Coartem (Artemether/Lumefantrine) Market?

Africa remains the largest regional market due to its high malaria burden and public health interventions.

Which segment accounted for the largest market share in the Global Coartem (Artemether/Lumefantrine) Market?

The tablet formulation segment accounted for the largest market share in 2023.

Who are the key market players in the Global Coartem (Artemether/Lumefantrine) Market?

Key players include Novartis AG, Cipla Ltd., Ipca Laboratories, Sanofi, and Guilin Pharmaceutical Co., Ltd.